Bexsero

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

zunanjo membrano semenskih mešičkov iz neisseria meningitidis skupina b (sev nz 98/254), rekombinantne Neisseria meningitidis skupina B fHbp fuzijski protein, rekombinantne Neisseria meningitidis skupina B NadA beljakovin, rekombinantne Neisseria meningitidis skupina B NHBA fuzijski protein

Available from:

GSK Vaccines S.r.l.

ATC code:

J07AH09

INN (International Name):

meningococcal group B Vaccine (rDNA, component, adsorbed)

Therapeutic group:

Meningococcal cepiva

Therapeutic area:

Meningitis, Meningokokni

Therapeutic indications:

Aktivna imunizacija proti invazivni bolezni, ki jo povzročajo sevi Neisseria meningitidis serogroup-B.

Product summary:

Revision: 33

Authorization status:

Pooblaščeni

Authorization date:

2013-01-13

Patient Information leaflet

                                27
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte v hladilniku.
Ne zamrzujte.
Shranjujte v originalni ovojnini za zagotovitev zaščite pred
svetlobo.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
GSK Vaccines S.r.l.,
Via Fiorentina 1,
53100 Siena,
Italija
_ _
_ _
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
_ _
EU/1/12/812/001
EU/1/12/812/002
EU/1/12/812/003
EU/1/12/812/004
_ _
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
_ _
16.
PODATKI V BRAILLOVI PISAVI
Sprejeta je utemeljitev, da Braillova pisava ni potrebna
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
28
PC
SN
NN
29
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
OVOJNINAH
NAPOLNJENA INJEKCIJSKA BRIZGA
_ _
1.
IME ZDRAVILA IN POT(I) UPORABE
Bexsero suspenzija za injiciranje
cepivo proti meningokokom B
i.m. uporaba
_ _
_ _
2.
POSTOPEK UPORABE
_ _
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP:
4.
ŠTEVILKA SERIJE
Lot:
5.
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
1 odmerek (0,5 ml)
6.
DRUGI PODATKI
30
B. NAVODILO ZA UPORABO
31
NAVODILO ZA UPORABO
BEXSERO SUSPENZIJA ZA INJICIRANJE V NAPOLNJENI INJEKCIJSKI BRIZGI
cepivo proti meningokokom skupine B (rekombinantno, komponentno,
adsorbirano)
PREDEN VI ALI VAŠ OTROK PREJMETE TO CEPIVO, NATANČNO PREBERITE
NAVODILO, KER VSEBUJE POMEMBNE
PODATKE ZA VAS IN VAŠEGA OTROKA!
-
Navodilo shranite. Morda ga boste želeli ponovno prebrati.
-
Če imate dodatna vprašanja, se posvetujte z zdravnikom ali
medicinsko sestro.
-
Cepivo je bilo predpisano vam osebno ali vašemu otroku.
-
Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom
ali medicinsko sestro.
Posvetujte se tudi, če opazite katere koli neželene učinke, ki niso
navedeni v tem navodil
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Bexsero suspenzija za injiciranje v napolnjeni injekcijski brizgi
cepivo proti meningokokom skupine B (rekombinantno, komponentno,
adsorbirano)
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
En odmerek (0,5 ml) vsebuje:
rekombinantna fuzijska beljakovina NHBA iz
_Neisseria meningitidis_
skupine B
1, 2, 3
50 mikrogramov
rekombinantna beljakovina NadA iz
_Neisseria meningitidis_
skupine B
1, 2, 3
50 mikrogramov
rekombinantna fuzijska beljakovina fHbp iz
_Neisseria meningitidis_
skupine B
1, 2, 3
50 mikrogramov
vezikli zunanje membrane (OMV – outer membrane vesicles) iz
_Neisseria _
_meningitidis _
skupine B sev NZ98/254, izmerjeno kot količina skupnih
beljakovin, ki vsebuje PorA P1.4
2
25 mikrogramov
1
izdelano v celicah
_E. coli_
s tehnologijo rekombinantne DNA
2
adsorbirano na aluminijev hidroksid (0,5 mg Al
3+
)
3
NHBA (Neisserial Heparin Binding Antigen - Neisseria heparin vezavni
antigen), NadA (Neisserial
adhesin A - Neisseria adhezin A), fHbp (factor H binding protein -
faktor H vezavna beljakovina)
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
suspenzija za injiciranje
Bela opalescentna tekoča suspenzija.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Cepivo Bexsero je indicirano za aktivno imunizacijo oseb, starih 2
meseca in več, proti invazivni
meningokokni bolezni, ki jo povzroča bakterija
_Neisseria meningitidis_
skupine B. Pred cepljenjem je
treba upoštevati vpliv invazivne bolezni v različnih starostnih
skupinah ter variabilnost epidemiologije
antigenov za seve skupine B v različnih geografskih področjih.
Glejte poglavje 5.1 za informacije o
zaščiti pred specifičnimi sevi skupine B.
To cepivo je treba uporabljati v skladu z uradnimi priporočili.
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
3
PREGLEDNICA 1:
POVZETEK ODMERJANJA
STAROST OB PRVEM
ODMERKU
OSNOVNA IMUNIZACIJA
PRESLEDKI MED
OSNOVNIMI
ODMERKI
POŽIVITVENI ODMEREK
DOJENČKI,
OD 2 DO 5 MESECEV
A
trije odmerki
po 0,5 ml
vsaj 1 mesec
da, en o
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 23-05-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 23-05-2023
Public Assessment Report Public Assessment Report Bulgarian 11-07-2018
Patient Information leaflet Patient Information leaflet Spanish 23-05-2023
Public Assessment Report Public Assessment Report Spanish 11-07-2018
Patient Information leaflet Patient Information leaflet Czech 23-05-2023
Public Assessment Report Public Assessment Report Czech 11-07-2018
Patient Information leaflet Patient Information leaflet Danish 23-05-2023
Public Assessment Report Public Assessment Report Danish 11-07-2018
Patient Information leaflet Patient Information leaflet German 23-05-2023
Public Assessment Report Public Assessment Report German 11-07-2018
Patient Information leaflet Patient Information leaflet Estonian 23-05-2023
Public Assessment Report Public Assessment Report Estonian 11-07-2018
Patient Information leaflet Patient Information leaflet Greek 23-05-2023
Public Assessment Report Public Assessment Report Greek 11-07-2018
Patient Information leaflet Patient Information leaflet English 23-05-2023
Public Assessment Report Public Assessment Report English 11-07-2018
Patient Information leaflet Patient Information leaflet French 23-05-2023
Public Assessment Report Public Assessment Report French 11-07-2018
Patient Information leaflet Patient Information leaflet Italian 23-05-2023
Public Assessment Report Public Assessment Report Italian 11-07-2018
Patient Information leaflet Patient Information leaflet Latvian 23-05-2023
Public Assessment Report Public Assessment Report Latvian 11-07-2018
Patient Information leaflet Patient Information leaflet Lithuanian 23-05-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 23-05-2023
Public Assessment Report Public Assessment Report Lithuanian 11-07-2018
Patient Information leaflet Patient Information leaflet Hungarian 23-05-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 23-05-2023
Public Assessment Report Public Assessment Report Hungarian 11-07-2018
Patient Information leaflet Patient Information leaflet Maltese 23-05-2023
Public Assessment Report Public Assessment Report Maltese 11-07-2018
Patient Information leaflet Patient Information leaflet Dutch 23-05-2023
Public Assessment Report Public Assessment Report Dutch 11-07-2018
Patient Information leaflet Patient Information leaflet Polish 23-05-2023
Public Assessment Report Public Assessment Report Polish 11-07-2018
Patient Information leaflet Patient Information leaflet Portuguese 23-05-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 23-05-2023
Public Assessment Report Public Assessment Report Portuguese 11-07-2018
Patient Information leaflet Patient Information leaflet Romanian 23-05-2023
Public Assessment Report Public Assessment Report Romanian 11-07-2018
Patient Information leaflet Patient Information leaflet Slovak 23-05-2023
Public Assessment Report Public Assessment Report Slovak 11-07-2018
Patient Information leaflet Patient Information leaflet Finnish 23-05-2023
Public Assessment Report Public Assessment Report Finnish 11-07-2018
Patient Information leaflet Patient Information leaflet Swedish 23-05-2023
Public Assessment Report Public Assessment Report Swedish 11-07-2018
Patient Information leaflet Patient Information leaflet Norwegian 23-05-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 23-05-2023
Patient Information leaflet Patient Information leaflet Icelandic 23-05-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 23-05-2023
Patient Information leaflet Patient Information leaflet Croatian 23-05-2023
Public Assessment Report Public Assessment Report Croatian 11-07-2018

View documents history